EGFR and lung carcinoma: The research and wide application of EGFR-TKI (Tyrosine kinase inhibitors) drugs, mainly including Gefitinib, Erlotinib, Icotinib, Afatinib, Dasatinib, and Osimertinib, have greatly improved the overall survival of patients with lung cancer with the EGFR gene mutation.